M2Gen, a health informatics solutions company focused on accelerating the discovery, development and delivery of precision medicine, has appointed Helge Bastian, Ph.D., as president and chief executive officer (CEO). Bastian succeeds M2Gen Executive Chair William S. Dalton, M.D., Ph.D., who has served as interim CEO since September 2018.
M2Gen®, spun out of the Moffitt Cancer Center in 2016, headquartered in Tampa, Florida, is a health informatics solutions company focused on accelerating the discovery and development of precision medicine. M2Gen partners with the USA’s leading cancer centers through the Oncology Research Information Exchange Network® (ORIEN) to implement the Total Cancer Care® (TCC) Protocol creating a large, cancer-focused data warehouse linking clinical and molecular data. Using this information, M2Gen helps biopharmaceutical companies address the greatest challenges in oncology drug development.
Dr. Bastian is an experienced executive and scientific leader with more than 27 years of international experience while contributing to the growth of leading life science and healthcare companies in Germany, Switzerland and the USA.
His expertise spans, molecular and synthetic biology including game-changing technologies such as genome editing, gene synthesis and re-programming, molecular and companion diagnostics, clinical research, drug development, pharmaceutical manufacturing and biobanking.
As M2Gen’s new CEO, he will focus on expanding the company’s business portfolio and growing the Oncology Research Information Exchange Network® (ORIEN), an alliance of biopharmaceutical companies and leading cancer centers, powered by M2Gen’s data and informatics platforms that work in collaboration to address the greatest challenges in oncology drug development. He will also join M2Gen’s Board of Directors.
“Dr. Bastian has a proven track record of building profitable and sustainable businesses in the life sciences and healthcare sectors including many years of experience in leading clinical research and biobanking organizations supporting precision medicine approaches. We are excited to have Dr. Bastian join M2Gen and lead our company to the next level as we deliver health information solutions that link patient-specific clinical and molecular data with the objective of developing and delivering personalized medicine for patients. With Dr. Bastian at the helm, M2Gen will continue to grow and advance the company’s mission to learn from each patient and proactively develop therapeutic options to meet patient needs.” – William S. Dalton, M.D., Ph.D., M2Gen Executive Chair, and Interim CEO
“I am very excited about M2Gen’s revolutionizing data-driven approach to precision medicine in such an important area as oncology that affects so many people’s lives. I look forward to bringing my leadership experiences from the life science and healthcare industry to M2Gen and taking the company to the next level of its exciting growth strategy.”
“Understanding a patient’s genetic predisposition and the real-time molecular patterns in a patient’s tumor in combination with his / her clinical data is paramount to unravel the molecular mechanisms responsible for cancer development, and for developing new drugs and therapies as well as for accurate patient enrolling to clinical trials and even for developing strategies for cancer prevention. M2Gen’s initiative to build this unique and growing healthcare ecosystem of cancer centers to support clinical and molecular data sharing from a large number of cancer patients via M2Gen’s platforms is designed to fundamentally change the way cancer is being studied and treated, and will accelerate the discovery and development of precision treatment options for patients.” – Helge Bastian, Ph.D., M2Gen President and Chief Executive Officer
Sources
- https://www.businesswire.com/news/home/20190814005077/en/M2Gen%C2%AE-Appoints-Dr.-Helge-Bastian-President-Chief
- https://www.crunchbase.com/organization/m2gen#section-overview
